Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting β-hydroxybutyrate levels in a phase IIa pilot study

Diabetes, Obesity and Metabolism

Volumn 19, Issue 6, 2017, Pages 814-821

  Henry, Robert R ^a,e   Dandona, Paresh ^b   Pettus, Jeremy ^a   Mudaliar, Sunder ^a,e   Xu, John ^c   Hansen, Lars ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c ASTRAZENECA   (United Kingdom)

^d BRISTOL MYERS SQUIBB   (United States)

^e VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

antidiabetic drug; continuous glucose monitoring (CGM); dapagliflozin; glycaemic control; insulin therapy; type 1 diabetes; hydroxybutyrate

Indexed keywords

3 HYDROXYBUTYRIC ACID; DAPAGLIFLOZIN; GLUCOSE; INSULIN; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CONTROLLED STUDY; DRUG EFFICACY; ENDOCRINE FUNCTION TEST; FEMALE; GLYCEMIC CONTROL; HUMAN; INFORMED CONSENT; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TO CARBOHYDRATE COUNTING TECHNIQUE; MAJOR CLINICAL STUDY; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; PILOT STUDY; POST HOC ANALYSIS; URINARY EXCRETION; YOUNG ADULT; ANALYSIS; BLOOD; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIET RESTRICTION; DOSE RESPONSE; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; MALE; PROCEDURES; URINE;

3-HYDROXYBUTYRIC ACID; ADULT; BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FASTING; FEMALE; GLUCOSE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PILOT PROJECTS;

EID: 85017383237     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12882     Document Type: Article

References (22)

1. 1c in youth with type 1 diabetes. Diabetologia. 2016;59(suppl 1):S95-96. Abstract no. 186. (presented at EASD annual meeting 2016).
2. Cleland SJ, Fisher BM, Colhoun HM, Sattar N, Petrie JR. Insulin resistance in type 1 diabetes: what is ‘double diabetes’ and what are the risks? Diabetologia. 2013;56(7):1462-1470.
3. Grunberger G, Abelseth JM, Bailey TS, et al. Consensus statement by the American Association of Clinical Endocrinologists/American College of Endocrinology insulin pump management task force. Endocr Pract. 2014;20(5):463-489.
4. Miller KM, Foster NC, Beck RW, et al. Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D exchange clinic registry. Diabetes Care. 2015;38(6):971-978.
5. Strachan MJ, Frier BM. Insulin Therapy: A Pocket Guide. London, England: Springer-Verlag; 2013.
6. Nauck MA. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther. 2014;8:1335-1380.
7. Tang W, Reele S, Hamer-Maansson JE, Parikh S, de Bruin TW. Dapagliflozin twice daily or once daily: effect on pharmacokinetics and urinary glucose excretion in healthy subjects. Diabetes Obes Metab. 2015;17(4):423-425.
8. Erondu N, Desai M, Ways K, Meininger G. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015;38(9):1680-1686.
9. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015;38(9):1687-1693.
10. Peters AL, Henry RR, Thakkar P, Tong C, Alba M. Diabetic ketoacidosis with canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in patients with type 1 diabetes. Diabetes Care. 2016;39(4):532-538.
11. Henry RR, Rosenstock J, Edelman S, et al. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study. Diabetes Care. 2015;38(3):412-419.
12. Monnier L, Colette C. Target for glycemic control: concentrating on glucose. Diabetes Care. 2009;32(suppl 2):S199-S204.
13. Sheikh-Ali M, Karon BS, Basu A, et al. Can serum beta-hydroxybutyrate be used to diagnose diabetic ketoacidosis? Diabetes Care. 2008;31(4):643-647.
14. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015;38(9):1638-1642.
15. Henry RR, Thakkar P, Tong C, Polidori D, Alba M. Efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes. Diabetes Care. 2015;38(12):2258-2265.
16. Pieber TR, Famulla S, Eilbracht J, et al. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab. 2015;17(10):928-935.
17. U.S. Food and Drug Administration. FDA drug safety communication: FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. 2015. http://www.fda.gov/Drugs/DrugSafety/ucm475463.htm. Accessed July 1, 2016.
18. European Medicines Agency. SGLT2 inhibitors: PRAC makes recommendations to minimise risk of diabetic ketoacidosis. 2016. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2016/02/WC500201890.pdf. Accessed July 1, 2016.
19. Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a “Thrifty substrate” hypothesis. Diabetes Care. 2016;39(7):1108-1114.
20. Bristol-Myers Squibb. Dapagliflozin evaluation in patients with inadequately controlled type 1 diabetes (DEPICT 1). 2016. https://clinicaltrials.gov/ct2/show/NCT02268214. Accessed July 1, 2016.
21. Bristol-Myers Squibb. Dapagliflozin evaluation in patients with inadequately controlled type 1 diabetes (DEPICT 2). 2015. https://clinicaltrials.gov/ct2/show/NCT02460978. Accessed July 1, 2016.
22. Polidori D, Sanghvi A, Seeley RJ, Hall KD. How strongly does appetite counter weight loss? Quantification of the feedback control of human energy intake. Obesity. 2016;24(11):2289-2295.